Individualized Decision Making in Transperineal Prostate Biopsy: Should All Men Undergo an Additional Systematic Biopsy?

August Sigle, Rodrigo Suarez-Ibarrola, Matthias Benndorf, Moritz Weishaar, Jonathan Morlock, Arkadiusz Miernik, Christian Gratzke, Cordula A. Jilg, and Markus Grabbert

Department of Urology, Faculty of Medicine, Medical Center—University of Freiburg, 79106 Freiburg, Germany
Department of Radiology, Faculty of Medicine, Medical Center—University of Freiburg, 79106 Freiburg, Germany
Berta-Ottenstein-Programme, Faculty of Medicine, University of Freiburg, 79110 Freiburg, Germany

Correspondence: august.sigle@uniklinik-freiburg.de; Tel.: +49-761-270-25820; Fax: +49-761-270-28960

Simple Summary: In the last few years, multiparametric magnetic resonance imaging (mpMRI) has been implemented in the diagnostic prostate cancer pathway for the identification of cancerous lesions, and consecutively, targeted fusion biopsy was implemented. In some cases, aggressive prostate cancer is missed by a targeted biopsy. To address this imperfection, additional systematic biopsy is recommended but may be harmful in terms of the additional diagnosis of indolent cancer, and the higher frequency of adverse events and resource expenditures. This study investigates whether all men should undergo an additional systematic biopsy within this clinically relevant trade-off. As a key finding, men with an mpMRI-lesion classified as PI-RADS 5 may obviate additional systematic biopsy. This was confirmed when we analyzed histopathological reclassification rates between biopsy and a subsequent radical prostatectomy.

Abstract: Background: In prostate cancer (PC) diagnosis, additional systematic biopsy (SB) is recommended to complement MRI-targeted biopsy (TB) to address the limited sensitivity of TB alone. The combination of TB+SB is beneficial for diagnosing additional significant PC (sPC) but harmful in terms of the additional diagnosis of indolent PC (iPC), morbidity, and resource expenditures. We aimed to investigate the benefit of additional SB and to identify predictors for this outcome. Methods: We analyzed the frequency of upgrading to sPC by additional SB in a retrospective single-center cohort of 1043 men. Regression analysis (RA) was performed to identify predictors for this outcome. Reclassification rates of ISUP grade groups between prostate biopsy and a subsequent radical prostatectomy were assessed. Results: Additional SB led to upgrading to sPC in 98/1043 men (9.4%) and to the additional diagnosis of iPC in 71/1043 (6.8%). In RA, men harboring a PI-RADS 2-4 lesion were more likely to have TB results upgraded by SB (p < 0.01) compared to PI-RADS 5 men. When analyzing reclassification rates, additional SB reduced the upgrading to sPC from 43/214 (20.1%) to 8/214 (3.7%). In the PI-RADS 5 subgroup, this difference decreased: 4/87 (4.7%) with TB only vs. 1/87 (1.2%) with TB+SB. Conclusion: Men with a PI-RADS 5 lesion may obviate additional SB.

Keywords: prostatic neoplasms; image-guided biopsy; fusion biopsy; biopsy strategy
over the unacceptable proportion of missed high-grade cancers when SB is omitted [3]. Among the main shortcomings of TB are (1) Reading errors: Misdiagnosing lesions due to misinterpretation; (2) Presence of non-MRI visible sPC; and (3) Targeting errors by the person performing the TB [4]. A recent meta-analysis evaluating cancer detection rates (CDR) for TB versus SB found that omitting SB would miss approximately 16% of sPC [5].

Since systematic cores increase the detection of iPC [5], morbidity [6], and resource expenditures, a compromise needs to be reached to limit SB in men that are more likely to benefit from it.

There is growing interest in determining if a subgroup of men might benefit from SB in addition to TB. Previous studies have identified the clinical setting (biopsy naïve, previous negative biopsy, active surveillance), age, prostate volume, MRI-lesion volume and the PI-RADS Score [7–9] predictive for upgrading to sPC by SB. A recent study proposed patients’ PI-RADS score as a promising tool to select the optimal biopsy strategy [10]. However, these findings are limited to a cohort who underwent transrectal prostate biopsy. Current guidelines favor the transperineal approach for prostate biopsy [11]. Moreover, the evaluation of reclassification rates of prostate cancer (PC) grade groups between prostate biopsy and a subsequent radical prostatectomy (RP) are missing. We aimed (1) to evaluate the frequency of upgrading to sPC by SB over TB and to identify predictors for this outcome; (2) to analyze CDRs by TB and TB+SB for transperineal prostate biopsy stratified by the identified parameters; and (3) to investigate reclassification rates of PC grade groups between prostate biopsy and a subsequent RP stratified by the identified parameters.

2. Patients and Methods

2.1. Study Population

We analyzed a retrospective single-center cohort of 1043 men (Total Cohort) who underwent prostate biopsy. The indication for biopsy was based on suspicious prostate-specific antigen (PSA) levels/dynamics, abnormal digital rectal examination, or as a part of an active surveillance routine. Men with very high PSA-levels (>20 ng/mL) and suspicion of locally advanced disease were included in this study.

Men who underwent a prostate biopsy between October 2015–May 2020 were included in the study. Men were excluded if only TB or only SB was conducted, or in the case of incomplete clinical data. Men who were diagnosed with PC and underwent RP within one year after biopsy were considered for further analysis (Prostatectomy Cohort). Data collection was approved by the local Ethics Committee (ETK 21-1191). The study was performed in accordance with the Declaration of Helsinki.

2.2. MR Imaging, Biopsy Procedure and Histopathological Analysis

All men had a pre-biopsy multiparametric magnetic resonance imaging (mpMRI) according to the current Prostate Imaging Reporting and Data System (PI-RADS) [12]. Image interpretation was performed by a group of board-certified radiologists as a part of the clinical routine and without central revision. Robot-assisted mpMRI/transrectal ultrasound fusion biopsy of the prostate (iSRobot Mona Lisa®, Biobot Surgical, Singapore) was performed as a combined procedure of TB plus synchronous SB. The Ginsburg protocol that addresses both sides of the prostate was applied for SB planning [13]. The median total number of cores taken was 35 (interquartile range (IQR) 31–40) with a median of 31 (IQR 26–34) systematic biopsy cores.

SB was not performed blinded to MRI lesions but was planned independently from TB. Eight different surgeons performed the standardized biopsy procedures that were included in this study. Procedural details were described previously [14]. Prostate biopsy was performed in lithotomy position via the transperineal route and under general anaesthesia. Antibiotic prophylaxis and local anaesthesia were not administered.

All biopsy cores were labelled, processed and analysed individually by a group of board-certified uropathologists and according to the International Society of Urological Pathology (ISUP) standards [15].
2.3. Data collection and Statistical Analysis

Demographic and clinical data were extracted by reviewing patients’ electronic medical records.

Baseline characteristics included age, previous biopsy and active surveillance status, PSA, prostate volume by MRI, mpMRI findings according to PI-RADS, zonal and side-specific information on target localization, index lesion volume, number of lesions, the number of biopsy cores and histopathological findings from prostate biopsy according to ISUP. The index lesion was defined as the lesion with the highest PI-RADS grade and in case of several equally assessed lesions the one with the largest volume was considered.

Continuous variables were described as median with interquartile range (IQR). Categorical variables were described with integers and percentages.

The primary endpoint of the study was the upgrading to sPC by additional SB. Clinically significant prostate cancer was defined as the presence of any PC classified as ISUP grade group 2 or higher. As secondary endpoints, we aimed to identify predictors for upgrading to sPC, and we assessed reclassification rates of ISUP grade groups between prostate biopsy and a subsequent RP. To identify predictors for the primary endpoint, we performed binary logistic regression analysis, including the following covariates: age, previous biopsy and active surveillance status, PSA, prostate volume, PI-RADS score, zonal and side-specific target localization, index lesion volume, number of lesions and the number of TB and SB cores. For the selection of variables in the multivariable analysis, we applied backward stepwise elimination. The binary cut-off for index lesion volume was set at 0.6 mL with respect to the variable’s median. The McNemar’s test was used to compare the detection rates of sPC. Moreover, we analyzed the overlap of 95% confidence intervals (CI) of the respective detection rates. p-value < 0.05 was considered statistically significant.

SPSS© software (SPSS statistics 27) was used for statistical analysis.

3. Results

3.1. Study Cohort

The enrollment and outcomes are presented in Figure 1. A total of 1121 men underwent prostate biopsy at the University Hospital Freiburg, Germany between October 2015–May 2020. Thirty-four men had no TB and 44 were excluded due to missing clinical data, resulting in a total cohort of 1043 men. Among these men, 222 patients (21.3%) underwent subsequent RP. Eight men of this subgroup were excluded because the time between biopsy and surgery exceeded one year, resulting in a prostatectomy cohort of 214 men.

3.2. Baseline Characteristics

Baseline characteristics and CDRs are illustrated in Table 1. Median age and PSA were 67.0 years (interquartile range (IQR) 61.0–72.0) and 8.8 ng/mL (6.0–12.6), respectively. In the prostatectomy cohort, the median age and PSA were 67.0 years and 9.3 ng/mL (6.3–14.0), respectively.

3.3. Cancer Detection Rates and Upgrading in Systematic Versus MRI–Targeted Biopsy

In the total cohort 649/1043 (62.2%) men were diagnosed with PC, with 521/1043 (50.0%) men harboring sPC. The CDRs of any PC and sPC by TB/SB were 48.7%/59.5% and 40.6%/46.3%, respectively.

Additional SB led to an upgrading to sPC in 98/1043 men (9.4%). Out of these men, 70/98 (71.4%) had no PC detected by TB and 28/98 (28.6%) were upgraded from iPC. Systematic biopsy led to the additional diagnosis of iPC in 71/1043 (6.8%) men.

3.4. Regression Analysis for the Upgrading to sPC by Systematic Biopsy

To identify predictors for upgrading to sPC by SB, we calculated both univariate and multivariate regression analysis (Table 2). In univariate regression analysis, we found the PI-RADS category to be significantly associated with the study’s primary endpoint: men harboring a PI-RADS lesion 2–4 were more likely to have TB results upgraded by...
SB ($p < 0.01$) compared to men with a PI-RADS 5 lesion. This finding was consistent in multivariable analysis. Moreover, we found patients with non-peripheral zone lesions being less likely to be upgraded by SB (OR 0.44 (0.23–0.85; $p < 0.01$)) compared to men with lesions localized in the peripheral zone. Smaller index lesions with volumes $< 0.6 \text{ mL}$ were associated with higher rates of upgrading to sPC by SB (OR 2.15 (CI 1.38–3.34; $p < 0.01$)). In addition, we found a significant association of prostate volume and the event of upgrading to sPC by SB (OR 0.99 (0.98–1.00, $p < 0.03$) in multivariate analysis.

**Figure 1.** Enrollment and Outcomes. All included men underwent combined biopsy (Bx) procedure with a combination of MRI-targeted biopsy plus synchronous systematic biopsy. For men diagnosed with PC different treatment options were offered (active surveillance, radiotherapy, and radical prostatectomy). Men undergoing a subsequent radical prostatectomy were considered for the analysis of reclassification rates of cancer grade groups between biopsy and wholemount specimen.
Table 1. Baseline Characteristics and Cancer Detection Rates. IQR—interquartile range; PSA—prostate specific antigen; PI-RADS—Prostate Imaging Reporting and Data System; ISUP—International Society of Urological Pathology.

| Characteristic                  | All Men Cases, n 1043 | Prostatectomy Cohort n 214 |
|--------------------------------|-----------------------|---------------------------|
| Age (years), median, IQR       | 67.0 (61.0–72.0)      | 67.0 (62.0–72.0)          |
| Previous Negative Biopsy, n (%)| 244 (23.4)            | 43 (20.1)                 |
| Active Surveillance, n (%)     | 141 (13.5)            | 29 (13.6)                 |
| PSA (ng/mL), median, IQR       | 8.8 (6.0–12.6)        | 9.3 (6.3–14.0)            |
| Volume (mL), median, IQR       | 53.0 (38.5–75.0)      | 47.6 (37.0–63.3)          |
| PI-RADS, n (%)                 |                       |                           |
| n/a                            | 54 (5.2)              | 8 (3.7)                   |
| 1                              | 0 (0.0)               | 0 (0)                     |
| 2                              | 43 (4.2)              | 6 (2.9)                   |
| 3                              | 170 (16.3)            | 17 (7.9)                  |
| 4                              | 530 (50.8)            | 97 (43.5)                 |
| 5                              | 246 (23.6)            | 86 (40.2)                 |
| Target Localization, n (%)     |                       |                           |
| Unilateral                     | 595 (57.0)            | 116 (54.2)                |
| Bilateral                      | 448 (43.0)            | 98 (45.8)                 |
| Non-peripheral Zone            | 221 (21.2)            | 33 (15.4)                 |
| Peripheral Zone                | 444 (42.6)            | 103 (48.1)                |
| Bi-zonal                       | 378 (36.2)            | 78 (36.4)                 |
| Index Lesion Volume (mL), median, IQR | 0.58 (0.32–1.14) | 0.64 (0.30–1.52) |
| Number of Lesions, n (%)       |                       |                           |
| 1                              | 481 (46.1)            | 104 (48.6)                |
| 2                              | 394 (37.8)            | 80 (37.4)                 |
| 3                              | 136 (13.0)            | 24 (11.2)                 |
| 4 or more                      | 32 (3.1)              | 6 (2.8)                   |
| Number of Cores, median, IQR   |                       |                           |
| Total                          | 35 (31–40)            | 34 (30–39)                |
| From Target                    | 5 (3–7)               | 4 (4–7)                   |
| Systematic                     | 31 (26–34)            | 30 (25–32)                |
| Cancer Grading according to ISUP, n (%) |                   |                           |
| No Cancer                      | 394 (37.8)            | n/a                       |
| 1                              | 128 (12.3)            | 8 (3.7)                   |
| 2                              | 174 (16.7)            | 71 (33.2)                 |
| 3                              | 142 (13.6)            | 82 (38.3)                 |
| 4                              | 162 (15.5)            | 26 (12.1)                 |
| 5                              | 43 (4.1)              | 27 (12.6)                 |

3.5. Cancer Detection Rates Stratified by PI-RADS Score

After the identification of the PI-RADS Score as a main influencing factor for the effect of SB, we stratified CDRs for TB vs. TB+SB by PI-RADS groups. The results are illustrated in Figure 2. With respect to the total cohort, the combined biopsy strategy (CB) diagnosed significantly more sPC and iPC compared to TB only (50.0% vs. 40.6%; p < 0.001 and 6.8% vs 2.9%, p < 0.001). This effect was consistent for the subgroup of men with PI-RADS 3 and PI-RADS 4 lesions, with an upgrading to sPC by SB in 20/170 (11.8%) and 62/530 (11.7%), respectively. When comparing the detection rates of sPC for CB versus TB in men classified as PI-RADS 5, there was no significant difference considering the overlap of 95% CIs: 78.0% (73.0–83.0%) for TB vs. 80.9% (75.9–85.8%) for CB. Omitting SB in men with a PI-RADS 5 lesion would have missed the diagnosis of any PC in 7/1043 (0.7%) men, with 1/1043 (0.1%) classified as ISUP 1, 3/1043 (0.3%) ISUP 2 and 3/1043 (0.3%) ISUP 3–5.
Table 2. Univariate and multivariate logistic regression analysis for upgrading to significant prostate cancer (ISUP2-5) by systematic biopsy. Backward stepwise elimination was applied for variable selection in multivariable analysis. sPC—significant prostate cancer (ISUP > 2); ISUP—International Society of Urological Pathology; OR—odds ratio; CI—confidence interval; PSA—prostate specific antigen; PI-RADS—Prostate Imaging Reporting and Data System. * \( p < 0.05; ** \( p < 0.01.

|                               | Univariate Analysis | Multivariate Analysis |
|--------------------------------|---------------------|-----------------------|
|                               | **OR (95% CI)**     | \( p \)               | **OR (95% CI)**     | \( p \)               |
| Age, years                    | 1.00 (0.97–1.03)    | 0.90                  |                       |                       |
| Previous Negative Biopsy      |                     |                       |                       |                       |
| \( \geq 1 \) vs. none         | 0.94 (0.58–1.52)    | 0.78                  |                       |                       |
| Active Surveillance           |                     |                       |                       |                       |
| Yes vs. No                    | 0.86 (0.44–1.66)    | 0.65                  |                       |                       |
| PSA level, ng/mL              | 0.99 (0.94–1.04)    | 0.72                  |                       |                       |
| Prostate volume, mL           | 0.99 (0.98–1.00)    | 0.18                  | 0.99 (0.98–1.00)     | <0.03 *               |
| PI-RADS Score                 |                     |                       |                       |                       |
| PI-RADS 5 vs.                 | Ref.                |                       |                       |                       |
| PI-RADS 4 vs.                 | 3.70 (1.66–8.28)    | <0.01 **              | 4.62 (2.08–10.28)    | <0.01 **              |
| PI-RADS 3 vs.                 | 4.43 (1.82–10.79)   | <0.01 **              | 5.54 (2.26–13.57)    | <0.01 **              |
| PI-RADS 2 vs.                 | 5.73 (1.80–18.26)   | <0.01 **              | 7.37 (2.41–22.53)    | <0.01 **              |
| Target Localization           |                     |                       |                       |                       |
| Unilateral vs. Bilateral      | 0.99 (0.64–1.54)    | 0.97                  |                       |                       |
| Non-peripheral Zone vs.       | 0.44 (0.23–0.85)    | <0.01 **              | 0.42 (0.22–0.81)     | <0.01 **              |
| Peripheral Zone               |                       |                       |                       |                       |
| Bizonal vs. Peripheral Zone   | 0.55 (0.33–0.90)    | 0.02 *                | 0.70 (0.44–1.20)     | 0.14                  |
| Index Lesion Volume           |                     |                       |                       |                       |
| <0.6 mL vs. \( \geq 0.6 \) mL| 2.15 (1.38–3.34)    | <0.01 **              |                       |                       |
| Number of lesions (n)         |                     |                       |                       |                       |
| 1 vs. >1                      | 0.99 (0.64–1.43)    | 0.97                  |                       |                       |
| Number of Target Cores (n)    | 0.98 (0.89–1.07)    | 0.61                  |                       |                       |
| Number of Systematic Cores (n)| 1.03 (0.99–1.07)    | 0.11                  |                       |                       |

3.6. Reclassification in Subsequent Radical Prostatectomy

As a secondary endpoint, we analyzed the reclassification rates of ISUP grade groups in RP specimen with regard to the initial biopsy results (Figure 3). 214/1043 (20.5%) men of the total cohort underwent radical prostatectomy. Combined biopsy mode reduced the upgrading to sPC from 43/214 (20.1%) to 8/214 (3.7%) compared to TB only. When analyzing the subgroup of men with a PI-RADS 5 lesion, this difference decreased: 4/87 (4.7%) vs. 1/87 (1.2%).
In our retrospective cohort, additional SB upgraded the diagnosis to sPC in 98/1043 men with PI-RADS 2–4 lesions, compared to 1/87 men with PI-RADS 5 lesions. These results are in accordance with previous studies [7,18–20]. When analyzing the subgroup of men with a PI-RADS 5 lesion, this difference was not statistically significant (n.s) when considering the overlap of 95% confidence intervals: sPC by TB was 78.0% (73.0–83.0%) vs. 80.9% (75.9–85.8%) for CB. TB—MRI-targeted biopsy; CB—combined biopsy = TB plus synchronous systematic biopsy.

In PC diagnosis, SB is recommended to complement TB to address the limited sensitivity of TB alone [11]. SB may be beneficial for diagnosing additional sPC but also harmful in terms of additional iPC, morbidity, and resource expenditures. This study aimed to investigate selection criteria for men who should undergo SB within this clinical relevant trade-off.

When analysing predictors for the upgrading to sPC by additional SB, we found that men with PI-RADS 2–4 lesions were more likely to have their TB results upgraded by SB compared to PI-RADS 5 men. These results are in accordance with previous studies [7,18–20]. In our study, the lowest frequency of upgrading was found in a multi-centre cohort where only eight SB cores were taken per patient [16]. In contrast to this, we applied the Ginsburg Scheme for SB and sampled a median of 26 systematic cores per patient. Acknowledging that targeting error as being the main reason for missing sPC by TB [4], the effect of additional SB might be mainly dependent on the surgeon’s experience. This reasoning is supported by the results of Sathianathen et al. who reported an upgrading of 11.6% by an additional 12-core SB in a cohort undergoing prostate biopsy by a group of surgeons without any experience in transperineal prostate biopsy before their study [8].

When analyzing predictors for the upgrading to sPC by additional SB, we found that the upgrade rate was significantly (p < 0.05) higher when analyzing the subgroup of men with a PI-RADS 5 lesion this effect turned neglectable (4.7% vs. 1.2%).

**Figure 2.** Cancer Detection Rates stratified by PI-RADS score and biopsy method. Additional systematic biopsy diagnosed significantly (*) more clinically significant prostate cancer (sPC) in the total cohort and in the subgroups of PI-RADS 2–4 men. For the group of men with a PI-RADS 5 lesion this difference was not statistically significant (n.s) when considering the overlap of 95% confidence intervals: sPC by TB was 78.0% (73.0–83.0%) vs. 80.9% (75.9–85.8%) for CB. TB—MRI-targeted biopsy; CB—combined biopsy = TB plus synchronous systematic biopsy.

**Figure 3.** Reclassification rates of ISUP grade groups between prostate biopsy and a subsequent radical prostatectomy. For the whole prostatectomy cohort, combined biopsy mode (CB, MRI-targeted biopsy + synchronous systematic biopsy) reduced the upgrading to significant prostate cancer from 20.1% when considering MRI-targeted biopsy (TB) results only to 3.7%. For the subgroup of PI-RADS 5 men this effect turned neglectable (4.7% vs. 1.2%). iPC—indolent prostate cancer; sPC—significant prostate cancer; PI-RADS—Prostate Imaging Reporting and Data System; Length of bars is calculated by the respective percentages.
4. Discussion

In PC diagnosis, SB is recommended to complement TB to address the limited sensitivity of TB alone [11]. SB may be beneficial for diagnosing additional sPC but also harmful in terms of additional iPC, morbidity, and resource expenditures. This study aimed to investigate selection criteria for men who should undergo SB within this clinically relevant trade-off.

4.1. Frequency of Upgrading to sPC by Additional Systematic Biopsy

In our retrospective cohort, additional SB upgraded the diagnosis to sPC in 98/1043 (9.4%) men. Previous studies similarly reported upgrading by adding SB but varied in the frequency of this event between 1.9–11.6% [8,16,17]. A recent meta-analysis found that omitting SB would even miss approximately 16% of sPC [5]. A reason for these deviations might originate from the various SB schemes applied and the different number of cores taken. The lowest frequency of upgrading was found in a multi-centre cohort where only eight SB cores were taken per patient [16]. In contrast to this, we applied the Ginsburg Scheme for SB and sampled a median of 26 systematic cores per patient. Acknowledging a targeting error as being the main reason for missing sPC by TB [4], the effect of additional SB might be mainly dependent on the surgeon’s experience. This reasoning is supported by the results of Sathianathen et al. who reported an upgrading of 11.6% by an additional 12-core SB in a cohort undergoing prostate biopsy by a group of surgeons without any experience in transperineal prostate biopsy before their study [8].

4.2. Predictors for Upgrading to sPC

When analysing predictors for the upgrading to sPC by additional SB, we found that men with PI-RADS 2-4 lesions were more likely to have their TB results upgraded by SB compared to PI-RADS 5 men. These results are in accordance with previous studies [7,18–20]. Ahdoot et al. proposed the patient’s PI-RADS score as a promising tool to select the optimal biopsy strategy in terms of omitting SB in men harbouring a PI-RADS 5 lesion [10].

Moreover, we found men with small lesions (<0.6 mL) and peripheral zone lesions more likely to have their diagnosis upgraded to significant disease by additional SB. The finding that smaller lesions are more probable to be missed by TB and thus lead to upgrading by an additional SB was previously described in a small cohort [9]. Altogether the option of an extended MRI-directed biopsy scheme is discussed in the current European Association of Urology guidelines to overcome the problem of targeting errors [11].

4.3. Stratification of Cancer Detection Rates by Patient’s PI-RADS Scores

Based on the finding that men harbouring PI-RADS lesions 2-4 were more likely to have their TB results upgraded by SB, we analyzed CDRs stratified by the patient’s respective PI-RADS score. In our cohort, we found men with PI-RADS 3 or PI-RADS 4 lesions more likely to be upgraded to sPC by an additional SB in 11.8% and 11.7% of cases, respectively. For PI-RADS 5 men, the added value of additional SB was reduced to 2.9% and without statistical significance compared to a TB-only strategy. Our results confirm those of Ahdoot and co-workers published for a cohort of 743 men who underwent TB plus synchronous 12-core extended SB via the transrectal route: 7.5% upgrading to sPC in PI-RADS 3 men, 8.0% in PI-RADS 4 and 2.5% in PI-RADS 5 [10]. The slightly higher upgrading frequency in our study might originate from the application of the Ginsburg Scheme in our cohort, which conveys a higher number of SB cores taken.

4.4. Reclassification in Subsequent Radical Prostatectomy

Previous studies showed that CB is more predictive for a patient’s true pathological grade group compared to TB alone and thus reduces diagnostic uncertainty with a consecutive decrease of both over- and undertreatment [17]. In accordance with these previously published data, we found that adding SB to TB could reduce upgrading to
sPC in a subsequent radical prostatectomy from 43/214 (20.1%) to 8/214 (3.7%). When analyzing the subgroup of men with a PI-RADS 5 lesion, this difference was negligible: 4/87 (4.7%) vs. 1/87 (1.2%). To our knowledge, this is the first subgroup analysis of a biopsy cohort for upgrading to sPC with wholemount specimen as the reference standard stratified by PI-RADS groups.

4.5. Limitations and Strengths of the Study

There were several limitations to the current study that must be acknowledged. The retrospective and single-center design limits the generalizability of our results. Moreover, our data originates from a cohort from a large academic center with a high level of expertise within the radiological and urological diagnostic prostate cancer pathways, which may not reflect the reality of care.

The study’s main strength is the evaluation of the additional effect of SB concerning reclassification rates in a subsequent radical prostatectomy, since this is fundamental to estimating the diagnostic uncertainty of the respective biopsy procedure. Moreover, this is the first study to evaluate the effect of additional SB stratified by PI-RADS groups in a large transperineal biopsy cohort.

4.6. Individualized Decision-Making

Our data suggest that the benefit of an additional SB in men with PI-RADS 5 lesions is limited since it only increases the rate of sPC diagnosis by 2.9%. This finding is confirmed when analyzing reclassification rates in a subsequent RP. Omitting SB in this group may result in fewer biopsy-related adverse events, a shorter operative time, lower procedure complexity, and a lower healthcare burden.

Nevertheless, the decision to perform only TB in PI-RADS 5 men must be taken individually. When considering focal therapy, CB provides information on the presence or absence of PC outside the MRI-lesion and thus is valuable for a precise surgical planning. Moreover, missing 2.9% of sPC in PI-RADS 5 men when omitting SB seems low but the risk threshold is ultimately subjective. Individual risk thresholds of both the physician and the patient must be considered when choosing the appropriate biopsy strategy.

5. Conclusions

Additional SB to complement TB conveys a trade-off between missing sPC on the one hand and the over diagnosis of iPC, and increased morbidity and resource expenditures on the other. We demonstrated that the benefit of an additional SB is small in men with a PI-RADS 5 lesion. This finding was confirmed when analyzing the diagnostic certainty of TB only versus TB+SB and comparing it with the reference standard of a subsequent radical prostatectomy. In conclusion, men with a PI-RADS 5 lesion may obviate additional SB.

Author Contributions: Conceptualization, A.S., R.S.-I. and M.G.; methodology, A.S., R.S.-I. and M.G.; formal analysis, A.S.; investigation, A.S., R.S.-I. and M.G.; resources, A.M., M.W. and J.M.; writing—original draft preparation, A.S., R.S.-I. and M.G.; writing—review and editing, all authors; supervision, M.B., C.G., C.A.J., A.M. and M.G. All authors have read and agreed to the published version of the manuscript.

Funding: The article processing charge was funded by the Baden-Wuerttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the University of Freiburg (approval number: ETK 21-1191, date of approval: 7 April 2021).

Informed Consent Statement: In accordance with the statement of the local ethics committee, patient consent was waived due to the retrospective design of our study with a large sample size and the consecutively inadequate resource expenditure. Moreover, when only including patients with informed consent, there is a high probability of a selection bias.
Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Ahmed, H.U.; El-Shater Bosaily, A.; Brown, L.C.; Gabe, R.; Kaplan, R.; Parmar, M.K.; Collaco-Moraes, Y.; Ward, K.; Hindley, R.G.; Freeman, A.; et al. Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound biopsy for prostate cancer (promis): A paired validating confirmatory study. *Lancet* 2017, 389, 815–822. [CrossRef] [PubMed]

2. Kasivisvanathan, V.; Rannikko, A.S.; Borghi, M.; Panebianco, V.; Mynderse, L.A.; Vaara, M.H.; Briganti, A.; Budäus, L.; Hellawell, G.; Hindley, R.G.; et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. *N. Engl. J. Med.* 2018, 378, 1767–1777. [CrossRef] [PubMed]

3. Rouvière, O.; Puech, P.; Renard-Penna, R.; Claudon, M.; Roy, C.; Mège-Lechevallier, F.; Decaussin-Petrucci, M.; Dubreuil-Chambardel, M.; Magaud, L.; Remontet, L.; et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naïve patients (MRI-first): A prospective, multicentre, paired diagnostic study. *Lancet Oncol.* 2019, 20, 100–109. [CrossRef] [PubMed]

4. Muthigi, A.; George, A.K.; Sidana, A.; Kongnyuy, M.; Simon, R.; Moreno, V.; Merino, M.J.; Choyke, P.L.; Turkbey, B.; et al. Magnetic resonance imaging-targeted biopsy versus systematic biopsy in the detection of prostate cancer: A systematic review and meta-analysis. *Eur. Urol.* 2019, 76, 284–303. [CrossRef] [PubMed]

5. Kohl, T.; Sigle, A.; Kuru, T.; Salem, J.; Rolfs, H.; Kowalke, T.; Suarez-Ibarrola, R.; Michaelis, J.; Binder, N.; Jilg, C.A.; et al. Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: Results of a multicenter trial with 30 days’ follow-up. *Prostate Cancer Prostatic Dis.* 2022, 25, 264–268. [CrossRef] [PubMed]

6. Kohl, T.; Sigle, A.; Kuru, T.; Salem, J.; Rolfs, H.; Kowalke, T.; Suarez-Ibarrola, R.; Michaelis, J.; Binder, N.; Jilg, C.A.; et al. Comprehensive analysis of complications after transperineal prostate biopsy without antibiotic prophylaxis: Results of a multicenter trial with 30 days’ follow-up. *Prostate Cancer Prostatic Dis.* 2022, 25, 264–268. [CrossRef] [PubMed]

7. Deniffel, D.; Perlis, N.; Ghai, S.; Girgis, S.; Healy, G.M.; Fleshner, N.; Hamilton, R.; Kulkarni, G.; Toi, A.; van der Kwast, T.; et al. Prostate biopsy in the era of MRI-targeting: Towards a judicious use of additional systematic biopsy. *Eur. Radiol.* 2022. [CrossRef] [PubMed]

8. Sathianathen, N.J.; Warlick, C.A.; Weight, C.J.; Ordonez, M.A.; Spilseth, B.; Metzger, G.J.; Murugan, P.; Konety, B.R. A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy. *BJU Int.* 2019, 123, 612–617. [CrossRef] [PubMed]

9. Coker, M.A.; Glaser, Z.A.; Gordetsky, J.B.; Thomas, J.V.; Rais-Bahrami, S. Targets missed: Predictors of MRI-targeted biopsy failing to accurately localize prostate cancer found on systematic biopsy. *Prostate Cancer Prostatic Dis.* 2018, 21, 549–555. [CrossRef] [PubMed]

10. Ahdoot, M.; Lebastchi, A.H.; Long, L.; Wilbur, A.R.; Gomella, P.T.; Mehralivand, S.; Daneshvar, M.A.; Yerram, N.K.; O’Connor, L.P.; et al. Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound fusion biopsy. *J. Urol.* 2017, 197, 327–334. [CrossRef] [PubMed]

11. Mottet, N.P.C.; van den Bergh, R.C.N.; Briers, E.; Gillessen, M.D.S.S.; Grummet, J.; van der Kwast, A.M.H.T.H.; Lam, T.B.; et al. A multicenter study of the clinical utility of nontargeted systematic transperineal prostate biopsies in patients undergoing pre-biopsy multiparametric magnetic resonance imaging. *Eur. Urol.* 2019, 76, 340–351. [CrossRef] [PubMed]

12. Turkbey, B.; Rosenkrantz, A.B.; Haider, M.A.; Padhani, A.R.; Villeirs, G.; Macura, K.J.; Tempany, C.M.; Choyke, P.L.; Cornud, F.; Margolis, D.J.; et al. Prostate imaging reporting and data system version 2. *Eur. Assoc. Urol.* 2020, 1, 11–13. [CrossRef] [PubMed]

13. Kuru, T.H.; Wadhwa, K.; Chang, R.T.M.; Echeverria, L.M.C.; Roethke, M.; Polson, A.; Rottenberg, G.; Koo, B.; Lawrence, E.M.; Seidenader, J.; et al. Definitions of terms, processes and a minimum dataset for transperineal prostate biopsies: A standardization approach of the ginsburg study group for enhanced prostate diagnostics: A standardization approach for transperineal prostate biopsies. *BJU Int.* 2013, 112, 568–577. [CrossRef] [PubMed]

14. Kroening, M.; Schaal, K.; Benndorf, M.; Roschinsky, M.; Lenz, P.; Krauss, T.; Drendel, V.; Kaysers, G.; Kurz, P.; Werner, M.; et al. Diagnostic accuracy of robot-guided, software based transperineal MRI/trus fusion biopsy of the prostate in a high risk population of previously biopsy negative men. *BioMed Res. Int.* 2016, 2016, 2384894. [CrossRef] [PubMed]

15. Epstein, J.I.; Allsbrook, W.C., Jr.; Amin, M.B.; Egevad, L.L.; Committee, I.G. The 2005 international society of urological pathology (isup) consensus conference on Gleason grading of prostatic carcinoma. *Am. J. Surg. Pathol.* 2005, 29, 1228–1242. [CrossRef] [PubMed]

16. Connor, M.J.; Egdell-Evans, D.; van Son, M.; Hosking-Jervis, F.; Bertoncelli Tanaka, M.; Reddy, D.; Bass, E.J.; Powell, L.; Ahmad, S.; Pegers, E.; et al. A multicenter study of the clinical utility of nontargeted systematic transperineal prostate biopsies in patients undergoing pre-biopsy multiparametric magnetic resonance imaging. *J. Urol.* 2020, 204, 1195–1201. [CrossRef] [PubMed]

17. Ahdoot, M.; Wilbur, A.R.; Reese, S.E.; Lebastchi, A.H.; Mehralivand, S.; Gomella, P.T.; Bloom, J.; Gurram, S.; Siddiqui, M.; Pinsky, P.; et al. MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis. *N. Engl. J. Med.* 2020, 382, 917–928. [CrossRef] [PubMed]
18. Nakanishi, Y.; Ito, M.; Fukushima, H.; Yokoyama, M.; Kataoka, M.; Ikuta, S.; Sakamoto, K.; Takemura, K.; Suzuki, H.; Tobisu, K.I.; et al. Who can avoid systematic biopsy without missing clinically significant prostate cancer in men who undergo magnetic resonance imaging-targeted biopsy? *Clin. Genitourin. Cancer* 2019, 17, e664–e671. [CrossRef] [PubMed]

19. Drobish, J.N.; Bevill, M.D.; Tracy, C.R.; Sexton, S.M.; Rajput, M.; Metz, C.M.; Gellhaus, P.T. Do patients with a pi-rads 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy? *Urol. Oncol.* 2021, 39, e231–e234. [CrossRef] [PubMed]

20. Gomez-Gomez, E.; Moreno Sorribas, S.; Valero-Rosa, J.; Blanca, A.; Mesa, J.; Salguero, J.; Carrasco-Valiente, J.; Lopez-Ruiz, D.; Anglada-Curado, F.J. Does adding standard systematic biopsy to targeted prostate biopsy in pi-rads 3 to 5 lesions enhance the detection of clinically significant prostate cancer? Should all patients with pi-rads 3 undergo targeted biopsy? *Diagnostics* 2021, 11, 1335. [CrossRef] [PubMed]